Companies › Enlivex Therapeutics
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Immunology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Allocetra Allogeneic peripheral blood mononuclear cells in apoptotic stable state | – | Phase 2 | Primary Knee Osteoarthritis; Temporomandibular Joint Osteoarthritis | Feb 2027 |
| Allocetra-OTS cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear c | – | Phase 1 | Osteoarthritis, Knee | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06748651 | Allocetra | Phase 1 | Temporomandibular Joint Osteoarthritis | Immunology | Feb 2026 |
| NCT06233474 | Allocetra-OTS | Phase 1 | Osteoarthritis, Knee | Immunology | Mar 2026 |
| NCT07580716 | Allocetra | Phase 2 | Primary Knee Osteoarthritis | Immunology | Feb 2027 |
Cash of $2m on 2025-12-31; operating cash outflow about $10m a year; runway about 2 months at that burn, to Mar 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway
No annotated target.
–
Quoin Pharmaceuticals Prime Gene Therapeutics Citryll Toll Biotech Co. Ltd. (Beijing) Ventus Therapeutics U.S.
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.